An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis

References

• Kainz K, Bauer MA, Madeo F, et al. Fungal infections in humans: the silent crisis. Microb Cell. 2020;7(6):143–145. doi: 10.15698/mic2020.06.718
   PubMed Web of Science ®Google Scholar
• Denning DW. Antifungal drug resistance: an update. Eur J Hosp Pharm. 2022;29(2):109–112. doi: 10.1136/ejhpharm-2020-002604
   PubMedGoogle Scholar
• Statistics | invasive candidiasis | candidiasis | types of diseases | fungal diseases | CDC. 2023 Jan 13. Available from: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html
   Google Scholar
• World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. 2022. Available from: https://www.who.int/publications/i/item/9789240060241
   Google Scholar
• Pfaller M, Castanheira M. Nosocomial candidiasis: antifungal stewardship and the importance of rapid diagnosis. Med Mycol. 2016;54(1):1–22. doi: 10.1093/mmy/myv076
   PubMed Web of Science ®Google Scholar
• McCarty TP, White CM, Pappas PG. Candidemia and Invasive Candidiasis. Infect Dis Clin North Am. 2021 Jun;35(2):389–413. doi: 10.1016/j.idc.2021.03.007
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Singh S. Multidrug-resistant Candida auris: an epidemiological review. Exp Rev Anti-Infective Ther. 2020 Jun;18(6):551–562. doi: 10.1080/14787210.2020.1750368. Epub 2020 Apr 13.PMID: 32237924.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50. doi: 10.1093/cid/civ933
   PubMed Web of Science ®Google Scholar
• Utz JP. General Side Effects. Ann Intern Med. 1964;61(2):340–343. doi: 10.7326/0003-4819-61-2-340
   PubMed Web of Science ®Google Scholar
• Kurtz MB, Rex JH. Glucan synthase inhibitors as antifungal agents. In: Advances in protein chemistry. Vol. 56. Academic Press; 2001. p. 423–475. doi: 10.1016/S0065-3233(01)56011-8
   Google Scholar
• Garcia-Effron G. Rezafungin—mechanisms of action, susceptibility and resistance: similarities and differences with the other echinocandins. J Fungi. 2020;6(4):262. doi: 10.3390/jof6040262
   Web of Science ®Google Scholar
• Krishnan BR, James KD, Polowy, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot. 2017;70(2):130–135. doi: 10.1038/ja.2016.89
   PubMed Web of Science ®Google Scholar
• Rezzayo (Rezafungin), Package Insert, Melinta Therapeutics. 2023.
   Google Scholar
• Bader J, Lakota E, Flanagan S, et al. Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrob Agents Chemother. 2018;62(6):10–128. doi: 10.1128/aac.02614-17
   Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY 2014 antifungal surveillance program. Antimicrob Agents Chemother. 2017;61(3). doi: 10.1128/aac.02045-16
   Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes C, Messer SA, et al. Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY program, 2016 to 2018). Antimicrob Agents Chemother. 2020 Mar 24;64(4):e00099–20. doi: 10.1128/AAC.00099-20. Print 2020 Mar 24.
   PubMed Web of Science ®Google Scholar
• Ham YY, Lewis JS, Thompson GR. Thompson GR 3rd. Rezafungin: a novel antifungal for the treatment of invasive candidiasis. Future Microbiol. 2021 Jan;16(1):27–36. doi: 10.2217/fmb-2020-0217
   PubMed Web of Science ®Google Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872–6879. doi: 10.1128/AAC.00701-16
   PubMed Web of Science ®Google Scholar
• Tóth Z, Forgács L, Locke JB, et al. In vitro activity of rezafungin against common and rare candida species and Saccharomyces cerevisiae. J Antimicrob Chemother. 2019 Dec 1;74(12):3505–3510. doi: 10.1093/jac/dkz390
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Locke JB, Daruwala P, et al. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant aspergillus fumigatus isolates and cryptic species. J Antimicrob Chemother. 2018 Nov 1;73(11):3063–3067. doi: 10.1093/jac/dky280
   PubMed Web of Science ®Google Scholar
• Jang SM, Hough G, Mueller BA. Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy. Blood Purif. 2018 [Epub 2018 Jun 14];46(3):214–219. doi: 10.1159/000489212
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Najvar LK, Jaramillo R, et al. Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01165–19. doi: 10.1128/AAC.01165-19. Print 2019 Oct.
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Rhomberg PR, Pfaller MA, et al. Evaluation of the post-antifungal effect of rezafungin and micafungin against Candida albicans, Candida parapsilosis and Candida glabrata. Mycoses. 2022;65(11):1040. doi: 10.1111/myc.13490
   PubMed Web of Science ®Google Scholar
• Chandra J, Ghannoum MA. CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms. Antimicrob Agents Chemother. 2018;62(2). doi: 10.1128/aac.01750-17
   Web of Science ®Google Scholar
• Cushion MT, Ashbaugh A. The long-acting echinocandin, rezafungin, prevents pneumocystis pneumonia and eliminates pneumocystis from the lungs in prophylaxis and murine treatment models. J Fungi. 2021 Sep 11;7(9):747. doi: 10.3390/jof7090747
   Web of Science ®Google Scholar
• Miesel L, Cushion MT, Ashbaugh A, et al. Efficacy of rezafungin in prophylactic mouse models of invasive candidiasis, aspergillosis, and pneumocystis pneumonia. Antimicrob Agents Chemother. 2021;65(3):e01992–20. doi: 10.1128/AAC.01992-20
   PubMed Web of Science ®Google Scholar
• Zhao Y, Prideaux B, Nagasaki Y, et al. Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother. 2017;61(10):e01009–17. doi: 10.1128/AAC.01009-17
   PubMed Web of Science ®Google Scholar
• Hager CL, Larkin EL, Long LA, et al. Evaluation of the efficacy of Rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother. 2018;73(8):2085–2088. doi: 10.1093/jac/dky153
   PubMed Web of Science ®Google Scholar
• Ong V, James KD, Smith S, et al. Pharmacokinetics of the novel echinocandin CD101 in multiple animal species. Antimicrob Agents Chemother. 2017;61(4):e01626–16. doi: 10.1128/AAC.01626-16
   PubMed Web of Science ®Google Scholar
• Carvalhaes CG, Klauer AL, Rhomberg PR, et al. Evaluation of rezafungin provisional CLSI clinical breakpoints and epidemiological cutoff values tested against a worldwide collection of contemporaneous invasive fungal isolates (2019 to 2020). J Clin Microbiol. 2022;60(4):e0244921. doi: 10.1128/jcm.02449-21
   PubMed Web of Science ®Google Scholar
• Sandison T, Ong V, Lee J, et al. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2):e01627–16. doi: 10.1128/AAC.01627-16
   PubMed Web of Science ®Google Scholar
• Flanagan S, Goodman DB, Jandourek A, et al. Lack of effect of rezafungin on QT/QTc interval in healthy subjects. Clin Pharmacol Drug Dev. 2020;9(4):456–465.
   PubMed Web of Science ®Google Scholar
• Ong V, Sandison T, Flanagan S. No Relevant Pharmacokinetic (PK) interaction between rezafungin and nine probe drugs: results from a drug-drug interaction (DDI) study. Biol Blood Marrow Transplant. 2019;25(3):S357.
   Web of Science ®Google Scholar
• Flanagan S, Walker H, Ong V, et al. Absence of clinically meaningful drug-drug interactions with Rezafungin: outcome of investigations. Microbiol Spectr. 2023 Jun 15;11(3):e0133923. doi: 10.1128/spectrum.01339-23. Epub 2023 May 8.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis. 2020;73(11):e3647–e55. doi: 10.1093/cid/ciaa1380
   Web of Science ®Google Scholar
• Thompson GR, Soriano A, Cornely OA, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023 Jan 7;401(10370):49–59. doi: 10.1016/S0140-6736(22)02324-8
   PubMed Web of Science ®Google Scholar
• Ordaya EE, Clement J, Vergidis P. The role of novel antifungals in the management of candidiasis: a clinical perspective. Mycopathologia. 2023 Dec;188(6):937–948. doi: 10.1007/s11046-023-00759-5. Epub 2023 Jul 20.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Perlin DS. Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. J Fungi. 2020 Sep 28;6(4):192.
   Web of Science ®Google Scholar
• Lakota EA, Ong V, Flanagan S, et al. Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data. Antimicrob Agents Chemother. 2018 May 25;62(6):e02603–17. doi: 10.1128/AAC.02603-17. Print 2018 Jun.
   PubMed Web of Science ®Google Scholar
• Rubino CM, Flanagan S. Population pharmacokinetics of rezafungin in patients with fungal infections. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0084221. doi: 10.1128/AAC.00842-21. Epub 2021 Aug 16.
   PubMed Web of Science ®Google Scholar
• Bader JC, Lakota EA, Flanagan S, et al. Overcoming the resistance hurdle: pharmacokinetic-pharmacodynamic target attainment analyses for rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrob Agents Chemother. 2018 May 25;62(6):e02614–7. doi: 10.1128/AAC.02614-17. Print 2018 Jun.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Zhao M, Andes DR. Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis Model. Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01556–19. doi: 10.1128/AAC.01556-19. Print 2019 Nov.
   PubMed Web of Science ®Google Scholar
• Jeck J, Jakobs F, Kurte MS, et al. Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis. JAC Antimicrob Resist. 2023 Jun 19;5(3):dlad079. doi: 10.1093/jacamr/dlad079. eCollection 2023 Jun.
   PubMedGoogle Scholar
• Jo J, Tran TT, Beyda ND, et al. Development of the invasive candidiasis discharge [I can discharge] model: a mixed methods analysis. Eur J Clin Microbiol Infect Dis. 2022 Oct;41(10):1207–13. doi: 10.1007/s10096-022-04473-w. Epub 2022 Aug 25.
   PubMed Web of Science ®Google Scholar